[EVOK] Evoke Pharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2 Change: -0.02 (-0.99%)
Ext. hours: Change: 0 (0%)

chart EVOK

Refresh chart

Description: Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on developing drugs for the treatment of gastroenterological disorders and diseases. It is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded in 2007 and is headquartered in Solana Beach, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-109.45% ROE-214.72% ROI
Current Ratio5.03 Quick Ratio Long Term Debt/Equity Debt Ratio0.39
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities530 K Cash From Investing Activities Cash From Operating Activities-3 M Gross Profit
Net Profit-3.52 M Operating Profit-3.45 M Total Assets12.62 M Total Current Assets12.57 M
Total Current Liabilities2.5 M Total Debt4.4 M Total Liabilities6.19 M Total Revenue
Technical Data
High 52 week3.33 Low 52 week0.59 Last close0.59 Last change-1.7%
RSI19.68 Average true range0.04 Beta0.98 Volume399.59 K
Simple moving average 20 days-13.03% Simple moving average 50 days-37.49% Simple moving average 200 days-73.64%
Performance Data
Performance Week-9.21% Performance Month-19.09% Performance Quart-80.44% Performance Half-78.3%
Performance Year-79.98% Performance Year-to-date-76.02% Volatility daily3.24% Volatility weekly7.25%
Volatility monthly14.85% Volatility yearly51.44% Relative Volume136.77% Average Volume972.07 K
New High New Low

News

2019-11-18 08:52:19 | What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s NASDAQ:EVOK Shareholder Register?

2019-11-13 08:30:00 | Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

2019-11-07 08:30:00 | Evoke Pharma Reports Third Quarter 2019 Financial Results

2019-09-20 17:14:09 | Foamix Initiates Phase II Study on Acne Combination Foam

2019-09-19 12:02:01 | When Will Evoke Pharma, Inc. NASDAQ:EVOK Come Back To Market?

2019-09-19 10:29:02 | Zynerba Releases Data on Epilepsy Candidate, Stock Down

2019-09-17 08:30:00 | Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

2019-08-08 05:30:00 | Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

2019-07-25 12:58:12 | Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA

2019-07-11 11:31:22 | Is Evoke Pharma, Inc. NASDAQ:EVOK A Volatile Stock?

2019-06-27 08:30:00 | Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA

2019-05-08 16:05:00 | Evoke Pharma Reports First Quarter 2019 Financial Results

2019-05-08 11:39:03 | Evoke Pharma EVOK to Post Q1 Earnings: What's in Store?

2019-04-29 09:13:24 | Investors Who Bought Evoke Pharma NASDAQ:EVOK Shares Five Years Ago Are Now Down 92%

2019-04-15 12:08:04 | Dr. Reddy's RDY Inks Deal to Acquire Portfolio of 42 ANDAs

2019-04-03 08:19:01 | The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

2019-04-02 06:00:00 | Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

2019-03-29 12:45:39 | Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

2019-03-14 08:30:00 | Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

2019-03-06 08:30:00 | Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

2019-03-04 08:30:00 | Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

2019-02-27 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

2019-01-07 08:30:00 | Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

2019-01-04 07:56:38 | Loss-Making Evoke Pharma, Inc. NASDAQ:EVOK Expected To Breakeven

2018-11-13 16:05:00 | Evoke Pharma Reports Third Quarter 2018 Results

2018-10-16 10:32:52 | Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc NASDAQ:EVOK

2018-10-08 18:28:10 | Generic-Drugs Stock Outlook: No Respite from Pricing Issues

2018-09-28 09:59:01 | Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

2018-08-17 09:12:01 | Evoke Pharma EVOK Announces FDA Acceptance of Gimoti NDA

2018-08-16 08:30:00 | Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review

2018-08-09 16:05:00 | Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights

2018-06-06 13:38:23 | At $2.8701, Is Evoke Pharma Inc NASDAQ:EVOK A Buy?

2018-06-04 07:30:00 | Evoke Announces FDA Submission of New Drug Application for Gimoti™

2018-05-14 10:27:15 | Evoke Pharma Inc NASDAQ:EVOK Is Expected To Breakeven

2018-05-14 06:30:00 | Evoke Pharma Reports First Quarter 2018 Results and Highlights

2018-05-10 07:30:00 | Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

2018-04-30 07:30:00 | Evoke Granted First Gender Specific Patent for Gimoti™

2018-03-26 07:30:00 | Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

2018-03-07 16:05:00 | Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

2018-03-07 12:00:00 | Evoke Pharma, Inc. to Host Earnings Call

2018-03-06 07:30:00 | Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

2018-03-05 07:30:00 | FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

2018-02-21 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results

2018-02-15 07:30:00 | Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™

2017-12-12 07:40:00 | Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint

2017-12-11 07:30:00 | Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission

2017-11-14 16:05:00 | Evoke Pharma Reports Third Quarter 2017 Results and Highlights

2017-11-14 12:00:00 | Evoke Pharma, Inc. to Host Earnings Call

2017-11-14 06:49:08 | A Look At Evoke Pharma Inc EVOK And The Healthcare Sector

2017-11-09 08:30:00 | Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific